Home > For Consumers > Low molecular weight heparin for...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-. doi: 10.1002/14651858.CD006681.pub3

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Low molecular weight heparin for prevention of venous thromboembolism in adults with lower‐leg immobilization in an outpatient setting

This version published: 2014; Review content assessed as up-to-date: June 03, 2013.

Link to full article: [Cochrane Library]

Plain language summary

Immobilization of the lower limb with plaster cast or brace in adult patients is associated with deep venous thrombosis (DVT). In order to prevent this complication preventive treatment with anticoagulants is often used, most commonly low molecular weight heparin (LMWH). Different indications for the use of LMWH are given in existing national guidelines. Therefore we searched the literature for trials on this topic, in order to develop an evidence‐based stand on this matter.

Six randomized controlled trials were found and judged to be of sufficient quality to use in a meta‐analysis. The trials involved 1490 patients: 750 patients received LMWH subcutaneously once daily; 740 patients received no prophylaxis or placebo. Incidence rates of DVT ranging from 4.3% to 40% were found in the control groups and ranging from 0% to 37% in the LMWH groups. There was a significant difference (odds ratio 0.49, 95% confidence interval 0.34 to 0.72). Further analysis showed a significant reduction of the occurrence of DVT when using LMWH in the following subgroups: operated patients; conservatively treated patients; patients with fractures; patients with soft tissue injuries; patients with below‐knee casts; a group with proximal thrombosis and a group with distal thrombosis.

There were few reported adverse effects in the treated patients. Two patients in the treatment group and one in the placebo group had to discontinue the LMWH due to major bleeding events. In the treatment group minor bleeding events were reported in up to 8% of cases. One patient developed facial eczema.

We conclude that LMWH should be considered in adult patients with immobilization of the lower leg to prevent occurrence of venous thromboembolism. It should not only be considered in patients with an above‐knee cast but also in patients with a below‐knee cast. LMWH can safely be used for this indication.

Abstract

Background: Immobilization of the lower leg is associated with venous thromboembolism (VTE). Low molecular weight heparin (LMWH) is an anticoagulant treatment which might be used in adult patients with lower‐leg immobilization to prevent deep venous thrombosis (DVT) and its complications. This is an update of the review first published in 2008.

Objectives: To assess the effectiveness of low molecular weight heparin for the prevention of venous thromboembolism in patients with lower‐leg immobilization in an ambulant setting.

Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator searched the Specialised Register (last searched June 2013) and CENTRAL (2013, Issue 5).

Selection criteria: Randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that described thromboprophylaxis by means of LMWH compared with no prophylaxis or placebo in adult patients with lower‐leg immobilization. Immobilization was by means of a plaster cast or brace.

Data collection and analysis: Two authors independently assessed trial quality and extracted data. The review authors contacted the trial authors for additional information if required. Statistical analysis was carried out using Review Manager (RevMan 5).

Main results: We included six RCTs fulfilling the above criteria with a total of 1490 patients. We found an incidence of VTE ranging from 4.3% to 40% in patients who had a leg injury that had been immobilized in a plaster cast or a brace for at least one week and who received no prophylaxis, or placebo. This number was significantly lower in patients who received daily subcutaneous injections of LMWH during immobilization (event rates ranging from 0% to 37%; odds ratio (OR) 0.49; fixed 95% confidence interval (CI) 0.34 to 0.72; with minimal evidence of heterogeneity with an I2 of 20%, P = 0. 29). Comparable results were seen in the following subcategories: operated patients, conservatively treated patients, patients with fractures, patients with soft tissue injuries, patients with proximal thrombosis, patients with distal thrombosis and patients with below‐knee casts. Complications of major bleeding events were extremely rare (0.3%) and there were no reports of heparin‐induced thrombocytopenia.

Authors' conclusions: Use of LMWH in outpatients significantly reduces VTE when immobilization of the lower leg is required.

Editorial Group: Cochrane Vascular Group.

Publication status: New search for studies and content updated (no change to conclusions).

Citation: Testroote M, Stigter WAH, Janssen L, Janzing HMJ. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐leg immobilization. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD006681. DOI: 10.1002/14651858.CD006681.pub3. Link to Cochrane Library. [PubMed: 24771319]

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 24771319

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...